STERIS plc operates in the critical healthcare sector, focusing on infection prevention solutions. With a diversified portfolio spanning healthcare, dental, and life sciences, the company has positioned itself as a formidable player in the market. However, careful attention is needed to monitor its debt levels relative to earnings.
The fundamental health of STERIS plc is primarily strong, with most metrics showing positive results although price valuation ratios remain areas of concern.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 4 | |
| Return on Assets | 4 | |
| Debt to Equity | 4 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historically, the company's fundamentals have remained stable, with consistent scores across most categories except for valuation ratios.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 7/22/2025 | 3 | 4 | 4 | 4 | 4 | 1 | 2 |
| Previous | 0 | 4 | 4 | 4 | 4 | 1 | 2 |
Analyst estimates suggest a positive outlook with a consensus rating suggesting potential upside in stock price.
| High | Low | Median | Consensus |
|---|---|---|---|
| $265 | $245 | $260 | $256.67 |
The majority of analysts recommend buying the stock, indicating positive sentiment surrounding the company's future performance.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 11 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
STERIS plc is well positioned within its industry due to its robust presence in multiple segments such as healthcare and life sciences. The overall strong analyst sentiment and solid fundamental scores, particularly in areas like cash flow and equity returns, enhance its appeal. However, potential investors must be mindful of its valuation ratios. While price targets suggest favorable stock performance, maintaining vigilant monitoring of global market dynamics is crucial for sustained growth.